Advancements in the domain of ophthalmology continue to expand the range of potential application areas for contact lenses. Presently, over 55 novel ophthalmic products have been developed or are being developed for the treatment of various ophthalmological disorders, diagnosis / monitoring of diseases and for restoring vision in the blind. The ongoing efforts to innovate in this domain are evident from the fact that more than 7,500 patents have been granted / filed since 2013.
To order this 230+ page report, which features 115+ figures and 110+ tables, please visit this link
The USD 3.7 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:
- Type of Product
- Contact Lenses
- Visual Prostheses
- Type of Lenses
- Therapeutic Contact Lenses
- Drug-eluting Contact Lenses
- Diagnostics and Monitoring Contact Lenses
- Target Indication
- Age-related Macular Degeneration
- Aniridia
- Diabetes
- Glaucoma
- Retinitis Pigmentosa
- Key Geographical Region
- North America
- EU5
- Asia-Pacific
The Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030 report features the following technologies, which we identified to be key players in this domain:
- EyePrint Prosthetics
- University of Washington
- Leo Lens Technology
- Baylor College of Medicine
- iBIONICS
Table of Contents
- Preface
2. Executive Summary
Introduction
- Market Overview
- Promotional Analysis
- Technology Profiles
- Patent Analysis
- Partnerships and Collaborations
- Emerging Trends on Social Media
- KOL Analysis
- Market Sizing and Forecast
- Interview Transcripts
- Conclusion
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/next-generation-contact-lenses-and-visual-prostheses-market-2019-2030/244.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=SNorth America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
